NCT06413680View on ClinicalTrials.gov

A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

September 23, 2024

Primary Completion Date

February 3, 2030

Study Completion Date

February 3, 2030

Conditions
MelanomaClear-Cell Renal-Cell Carcinoma (ccRCC)Advanced Solid Tumors
Interventions
DRUG

REGN10597

Administered as an intravenous (IV) infusion

Trial Locations (11)

11042

RECRUITING

Northwell Health, Lake Success

15232

RECRUITING

University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh

27514

RECRUITING

University of North Carolina at Chapel Hill, Chapel Hill

49546

RECRUITING

Start Midwest Cancer Research, Grand Rapids

60637

RECRUITING

University of Chicago, Chicago

77030

RECRUITING

MD Anderson Cancer Center, Houston

78229

RECRUITING

Next Oncology, San Antonio

RECRUITING

The Start Center for Cancer Care, San Antonio

90033

RECRUITING

Usc Norris Comprehensive Cancer Center, Los Angeles

94143

RECRUITING

University of California San Francisco (UCSF), San Francisco

06473

RECRUITING

Yale School of Medicine, North Haven

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY